Apellis Pharmaceuticals, Inc. Income Statement
APLS / Health Care|11 years of annual SEC 10-K data (FY2015-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 11 fiscal years. All figures from audited SEC 10-K filings.
Apellis Pharmaceuticals, Inc. reported $1.0B in revenue and $22M in net income for FY2025. Revenue has grown at a 32.0% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $781.4M | $396.6M | $75.4M | $66.6M | $250.6M | - | - | - | - | - |
| SG&A Expense | $550.3M | $501.1M | $500.8M | $277.2M | $176.8M | $139.4M | $67.0M | $22.6M | $10.5M | $4.3M | $6.4M |
| R&D Expense | $295.9M | $327.6M | $354.4M | $387.2M | $345.9M | $299.9M | $221.0M | $105.3M | $40.3M | $23.0M | $13.7M |
| Operating Income | $55.4M | -$165.0M | -$517.1M | -$594.6M | -$536.3M | -$213.7M | -$288.0M | -$127.9M | -$50.8M | -$27.3M | -$46.6M |
| Interest Expense | - | - | - | $5.7M | $12.1M | $3.6M | - | - | - | - | - |
| Income Tax | $1.7M | $1.2M | $2.1M | $669.0K | $352.0K | $1.8M | - | - | - | - | - |
| Net Income | $22.4M | -$197.9M | -$528.6M | -$652.2M | -$746.4M | -$344.9M | -$304.7M | -$127.5M | -$51.0M | -$27.1M | -$46.5M |
| EPS (Basic) | -$4.45 | -$6.15 | -$8.84 | -$4.59 | - | - | - | - | - | - | - |
| EPS (Diluted) | -$4.45 | -$6.15 | -$8.84 | -$4.59 | -$4.90 | -$2.34 | - | - | - | - | - |
| Shares Outstanding | 124.5M | 119.6M | 110.8M | 97.5M | 76.1M | 63.9M | 62.2M | 54.4M | 13.9M | 8.4M | 5.8M |
| Operating Margin | 5.5% | -21.1% | -130.4% | -788.4% | -805.7% | -85.3% | - | - | - | - | - |
| Profit Margin | 2.2% | -25.3% | -133.3% | -864.7% | -1121.3% | -137.6% | - | - | - | - | - |